What Congress and the FDA Are Doing After the Secret Shopper Study
The July 2026 secret shopper study generated real regulatory attention, not just headlines. Here's what's actually happening at the federal level in response.
FDA response
The FDA has continued issuing warning letters to individual telehealth companies for specific compliance issues — over 30 were issued to GLP-1 telehealth companies in the months surrounding the study's publication, though these individual actions predate and continue independent of the study itself, addressing specific violations rather than industry-wide standards directly.
Congressional attention
Studies like this one tend to inform broader policy conversations about telehealth prescribing standards, though translating a single study into binding federal regulation is a slower, more deliberative process than a single news cycle suggests. Any specific legislative response would need to move through committee review and the standard legislative process.
What to watch for
- Additional FDA warning letters to specific platforms named in follow-up reporting
- State medical board actions, which often move faster than federal legislation
- Industry self-regulation efforts, as reputable platforms differentiate themselves post-study
Sesame Care From $29
A licensed provider network operating within current regulatory standards.
Embody GLP1 From consult
Documented clinical review process ahead of any regulatory mandate.
Visit Embody GLP1 →Paid linkWhat this means for you right now
Regulatory change moves slower than the news cycle. Your best protection today is the verification steps covered throughout this site — not waiting for policy to catch up before making an informed choice.